Crinetics Pharmaceuticals, Inc. filings document a commercial-stage pharmaceutical company focused on endocrine diseases and endocrine-related tumors. Its 8-K reports include financial results and business updates tied to PALSONIFY product revenue, clinical development activity, regulatory matters, and corporate presentations. The filings also identify the company’s common stock, traded under CRNX on the Nasdaq Global Select Market.
Crinetics’ regulatory record also includes proxy materials covering governance and executive compensation, as well as current reports on officer responsibilities, executive departures, consulting arrangements, and changes in the company’s independent registered public accounting firm. These disclosures place PALSONIFY commercialization and endocrine pipeline development within formal reporting categories for operations, governance, controls, and capital-market status.
Crinetics Pharmaceuticals Chief Operating Officer Jeff E. Knight sold 9,911 shares of common stock in open-market transactions. The sales on March 16, 2026 were executed at volume-weighted average prices of $37.11 and $37.77 per share.
According to the disclosure, these shares were sold to cover tax withholding obligations arising from the vesting of previously granted restricted stock units and were carried out by a broker under a Rule 10b5-1 trading plan. After the transactions, Knight directly holds 112,018 shares of Crinetics common stock.
Crinetics Pharmaceuticals Chief Scientific Officer Stephen F. Betz reported selling a total of 10,612 shares of common stock on March 16, 2026 in open-market transactions. One block of 6,371 shares was sold at a volume-weighted average price of $37.11 per share, and another 4,241 shares at $37.77 per share.
According to the footnotes, these sales were made to cover his tax withholding obligations upon the vesting of previously granted restricted stock units and were executed by a broker under a pre-arranged Rule 10b5-1 trading plan. After these transactions, Betz directly holds 137,101 shares of Crinetics common stock.
Crinetics Pharmaceuticals President & CEO Richard Scott Struthers reported tax-related share sales. On March 16, 2026, he sold a total of 21,981 shares of common stock in open-market transactions, including 13,196 shares at a volume-weighted average price of $37.11 and 8,785 shares at $37.77.
According to the disclosure, these shares were sold by a broker to cover the CEO's tax withholding obligations upon the vesting of restricted stock units granted on February 28, 2022, March 1, 2023, and March 4, 2024, under a Rule 10b5-1 trading plan. After the sales, he directly holds 404,778 shares of common stock and has additional indirect holdings through several family trusts and his spouse.
CRNX: Notice of proposed and recent insider sales of Common Stock
The filing lists proposed transactions and recent dispositions by an insider. It shows a proposed exercise of stock options to sell 15,000 shares03/18/2026 and proposed settlement of 9,756 Restricted Stock Units03/15/2026. The filing also discloses three 10b5-1 sales of 5,000 shares each01/02/2026, 02/02/2026, and 03/02/2026 with proceeds of $232,590.50, $247,485.50, and $202,234.00, respectively.
Crinetics Pharmaceuticals director Rogerio Vivaldi Coelho sold 5,000 shares of Common Stock in open-market transactions. The sales occurred on March 12, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025, meaning the trades were scheduled in advance.
The transactions comprised 4,477 shares at a volume-weighted average price of $36.08 and 523 shares at a volume-weighted average price of $36.77, within disclosed intraday price ranges. Following these sales, he directly held 16,300 shares of Crinetics Pharmaceuticals common stock.
Crinetics Pharmaceuticals director Stephanie Okey reported an open-market sale of 3,000 shares of common stock at $39.67 per share on March 3, 2026. The trade was executed automatically under a Rule 10b5-1 trading plan adopted on November 19, 2025, and she now holds 13,300 shares.